前收市價 | 120.74 |
開市 | 122.50 |
買盤 | 122.15 x 1000 |
賣出價 | 123.69 x 1800 |
今日波幅 | 120.93 - 123.24 |
52 週波幅 | 69.08 - 124.00 |
成交量 | |
平均成交量 | 199,636 |
市值 | 3.483B |
Beta 值 (5 年,每月) | 1.39 |
市盈率 (最近 12 個月) | 21.57 |
每股盈利 (最近 12 個月) | 5.70 |
業績公佈日 | 2024年8月05日 |
遠期股息及收益率 | 7.60 (6.29%) |
除息日 | 2024年6月28日 |
1 年預測目標價 | 130.80 |
The reclassification of marijuana as a schedule III drug continues to move closer. The DEA continues to push to reclassify marijuana as a less dangerous drug. That promises to improve the prospects of cannabis stocks. That said, there are a handful of cannabis stocks that thrive with or without reforms. While the reforms are certainly welcome, there is a subgroup of cannabis stocks that have defied broader trends and are performing well. These companies are generally much closer to — or have alr
The Russell 2000 index holds the smallest companies within the Russell 3000 index. The Russell 2000 is useful for investors seeking to invest in small-cap companies. It gauges the overall health of the small-cap market and provides a reference point for finding small-cap stocks that may be solid investment opportunities. Within the Russell 2000, there are a number of undervalued stocks that can offer investors incredible returns. Below, I choose some of the most undervalued companies within the
The cannabis market is set for significant growth, driven by increasing legalization and consumer demand. Several pot stocks are poised for high returns, reflecting broader market trends. Several things are pushing the needle for these pot stocks to reach new highs. The global cannabis market is projected to grow at a compound annual growth rate (CAGR) of over 20% in the next few years. This growth is fueled by rising medical and recreational use. As more regions legalize cannabis, regulatory fr